![]() ![]() This chapter describes the basics of OCT technology and its clinical applications in retinal disorders. Thus, OCT has revolutionized the practice of ophthalmology and, in particular the diagnosis and management of patients with retinal disease. With the introduction of Spectral/ Fourier Domain OCT (SD-OCT, FD-OCT) and Swept Source OCT (SS-OCT), there is greater tissue resolving power, significantly higher scan density, and faster data acquisition than original Time Domain OCT. Originally developed in 1991 by Huang et al, OCT technology has continually evolved and expanded within ophthalmologyand has been explored in a wide range of clinical applications. ![]() The other authors have no conflicts of interest to declare.Optical Coherence Tomography is a powerful noninvasive imaging modality that performs high resolution, micron-scale, cross-sectional imaging of the retina. Stone reports receiving speaker or other honoraria from Cook, Terumo, Qool Therapeutics and Orchestra Biomed, being a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, and Matrizyme, and holding equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. West reports being an employee/stockholder of Abbott. Rapoza reports being an employee of Abbott. Zhang: reports being an employee of Abbott. Mintz reports honoraria from Boston Scientific, Philips, Terumo, and Medtronic. Matsumura reports being a consultant for Terumo Corporation. Akasaka reports honoraria and grants from Abbott Vascular Japan, and institutional grants from Boston Scientific, Nipro, and Terumo. Guagliumi reports institutional research grant support from Abbott Vascular, Boston Scientific, and Infraredx, and being a consultant for Abbott Vascular and Boston Scientific. ![]() Maehara reports institutional grant support from Abbott Vascular and Boston Scientific, and reports being a consultant for Conavi Medical Inc. Ali reports institutional research grants to Columbia University and the Cardiovascular Research Foundation from Abbott and Cardiovascular Systems Inc., being a consultant for Abbott, Abiomed, Acist Medical, Amgen, AstraZeneca, Boston Scientific, Cardinal Health, and Opsens Medical, and holding equity in Shockwave Medical. An appropriately powered trial, including only complex patients and lesions, is underway to substantiate the potential clinical benefit of OCT-guided PCI. In this underpowered study, OCT-guided PCI of non-complex lesions did not show a statistical difference in clinical outcomes at 12 months compared with IVUS or angiography guidance. No independent predictors of 12-month stent-related clinical events were identified from final OCT. There were no significant differences in the rates of TLF (2.0% OCT, 3.7% IVUS, 1.4% angiography), MACE (9.8% OCT, 9.1% IVUS, 7.9% angiography), or any of the individual components of these outcomes among the groups. Target lesion failure (TLF) and major adverse cardiovascular events (MACE) at 12 months were adjudicated by a blinded clinical events committee. OCT-guided PCI, using an external elastic lamina-based protocol, was compared to operator-directed IVUS-guided or angiography-guided PCI. The aim of the present study was to report the 12-month clinical follow-up data from the ILUMIEN III study. Whether these differences impact on clinical outcomes is unknown. In the ILUMIEN III trial, among 450 randomised patients with non-complex lesions undergoing percutaneous coronary intervention (PCI), optical coherence tomography (OCT) guidance led to greater stent expansion than angiography guidance, similar minimal stent area compared to both intravascular ultrasound (IVUS) guidance and angiography guidance, and lower rates of uncorrected dissection and malapposition than both IVUS guidance and angiography guidance. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |